Stomach Metastasis in a Patient with Prostate Cancer 4 Years after the Initial Diagnosis: A Case Report and a Literature Review

Bılıcı, Ahmet; Dikilitaş, Mustafa; Ton, Özlem; Bagli, Bekir Selim; Selçukbiricik, Fatih

doi:10.1155/2012/292140

Cited by 8 publications

(14 citation statements)

References 11 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastric metastasis is followed by other metastatic lesions. 4 , 5 However, in this case we only found a gastric lesion, and CT and bone scintigraphy did not reveal any metastatic lesions. To the best of our knowledge, a solitary gastric metastasis arising from a prostate tumor has not been reported to date.…”

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase

Hakozaki

Murata

Yokoyama

et al. 2018

Urology Case Reports

View full text Add to dashboard Cite

We report a case with prostate cancer and gastric neuroendocrine carcinoma. A 72-year old male presented with a gastric lesion 5 months after radical prostatectomy. The lesion was immunohistochemically positive for PSA, alpha-methylacyl-CoA racemase, synaptophysin, and chromogranin A, but negative for androgen receptor (AR). Differentiating gastric neuroendocrine carcinoma from gastric metastasis of prostate cancer is difficult, as both lesions exhibit similar acinar cell proliferation with prominent nucleoli.1 We discuss the diagnostic process of this case and how AR was a useful specific marker for diagnosing primary gastric neuroendocrine carcinoma.

show abstract

Section: Discussionmentioning

confidence: 50%

“…Gastric metastasis often arises from high-risk prostate cancer. 4 , 5 The initial PSA level was 7.61 ng/ml and the Gleason score of the prostatectomy was 3 + 4. Bilici et al reported a gastric metastasis arising from a prostate tumor with a Gleason score of 3 + 4, 5 but the PSA level was 244.8 ng/ml before treatment.…”

Section: Discussionmentioning

confidence: 99%

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase

Hakozaki

Murata

Yokoyama

et al. 2018

Urology Case Reports

View full text Add to dashboard Cite

show abstract

“…Metastatic gastric tumor of prostate cancer is rare and only 13 cases have been reported to date [2][3][4][5][6][7][8][9][10][11][12][13][14]. Time to metastasis to the stomach from a diagnosis of primary prostate cancer varies (identified simultaneously to 10 years later).…”

Section: Discussionmentioning

confidence: 99%

“…Among other cancers, bone and the lung are the most common distant metastatic sites in prostate cancer, which is rarely observed in the stomach/bowel (1.8%) [2]. Thirteen cases of metastatic prostate cancer to the stomach were reported in the English literature to date [3][4][5][6][7][8][9][10][11][12][13][14]. Most were diagnosed by biopsy with immunohistochemistry (IHC) of prostatespecific antigen (PSA), but only one case diagnosed as primary gastric cancer because of negative PSA staining was resected endoscopically [12].…”

Section: Introductionmentioning

confidence: 99%

A rare case of PSA-negative metastasized prostate cancer to the stomach with serum CEA and CA19-9 elevation: a case report

et al. 2020

View full text Add to dashboard Cite

Background Metastatic cancer to the stomach is relatively rare. Prostate-specific antigen (PSA) is a reliable biomarker used in the screening and management of patients with prostate cancer. However, it is difficult to definitively diagnose a PSA-negative metastatic gastric tumor of prostate cancer because the cancer sometimes resembles primary gastric cancer in clinical images. It is also difficult to distinguish metastatic cancer from primary cancer even in the pathological examination of biopsy samples when the lesion is poorly differentiated adenocarcinoma. There is a possibility that the characteristics of the cancer are changed during treatment such as chemotherapy or radiation therapy. Therefore, careful consideration is required for surgical indication. Case presentation A 60-year-old male underwent radical prostatectomy and subsequent radiation therapy for advanced prostate cancer (pT3N1M0) 10 years previously, and hormone therapy was started for metachronous multiple bone metastasis 10 months before. Upper gastrointestinal endoscopy revealed an irregular depressed lesion with a convergence of folds at the greater curvature of the upper gastric body. Biopsy showed poorly differentiated adenocarcinoma that was negative for PSA upon immunohistochemistry. He had high serum carcinoembryonic antigen (CEA) (946.1 ng/ml) and carbohydrate antigen 19-9 (CA19-9) (465.1 U/ml) levels with no elevation of PSA (0.152 ng/ml). The tumor was diagnosed as primary gastric cancer based on the clinical imaging and pathological examination of the biopsy sample including the PSA staining. Based on the diagnosis, laparoscopic proximal gastrectomy with lymphadenectomy was performed. However, pathological examination of the resected specimen revealed poorly differentiated adenocarcinoma that was positive for other prostate markers such as androgen receptor. Thus, the patient was diagnosed with metastasized prostate cancer to the stomach. Conclusions We report a case of metastatic gastric cancer of prostate cancer 10 years after radical prostatectomy. In the present case, it was difficult to diagnose a metastatic gastric tumor of prostate cancer preoperatively, because of its resemblance to primary gastric cancer without PSA expression and no serum PSA elevation. Although a rare case entity, it is important to consider the possibility of a metastatic gastric tumor when the surgical indication is determined in cases with another co-existing cancer.

show abstract

“…Six of the patients were known to have prostate cancer prior to the diagnosis of gastric metastases, and prostate cancer was diagnosed in one patient after upper endoscopy with biopsy and confirmation on immunohistochemical staining 8-13. Although rare, metastases to other sites in the GI tract, such as the small bowel and esophagus, have been reported 14,15.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach

Koop

Brauhmbhatt

Lewis

et al. 2017

ACG Case Reports Journal

View full text Add to dashboard Cite

We present a rare case of gastrointestinal (GI) bleeding associated with metastatic prostate adenocarcinoma to the stomach. Prostate cancer, which is the most common noncutaneous malignancy among men, rarely spreads to the stomach, with only 7 cases reported in the English literature. Symptoms may include abdominal pain, nausea, vomiting, and GI bleeding. Our patient was treated with epinephrine injection and bipolar cautery, but GI bleeding recurred 7 months later when he had worsening of his thrombocytopenia while using ibuprofen.

show abstract

Stomach Metastasis in a Patient with Prostate Cancer 4 Years after the Initial Diagnosis: A Case Report and a Literature Review

Cited by 8 publications

References 11 publications

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase

Gastric neuroendocrine carcinoma with positive staining for prostate cancer markers including prostate-specific antigen and alpha-methylacyl-CoA racemase

A rare case of PSA-negative metastasized prostate cancer to the stomach with serum CEA and CA19-9 elevation: a case report

Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach

Contact Info

Product

Resources

About